Interview with Worwick Anderson, NHMRC,
Would you begin by outlining the key milestones & achievements of the NHMRC in the past four years? The first point is the development of our initiatives on an international…
Address: PO Box 196 Hawthorn Victoria 3122
Tel: (03) 8823 7333
Web: http://www.servier.com.au/home/default.asp
In just over 20 years, turnover has increased from $1 million in 1984 to $107 million for 2009. The number of people employed has risen steadily. The Sales force has grown from 6 representatives in 1984 spread across all Australian regions to in excess of 120 representatives today, but has maintained its reputation throughout this time as being amongst one of the best trained, most professional and most productive in Australia.
Servier’s activities in Australia commenced in 1979 with the launch of the anti-diabetic agent- Diamicron
Pivotal development work for the group’s flagship product Coversyl, which led to more than 30 publications from Australian researchers prior to marketing approval, culminated with the launch of Coversyl 2mg and 4mg in 1992.
In 1999 The International Centre for Therapeutic Research was established in Australia- The first outside of Europe and now has a staff in excess of 30 involved in phase l,ll and lll clinical research.
By January 1999 the company had outgrown it’s head office of 15 years and moved to it’s new purpose built office in Hawthorn, Melbourne, which saw the divisions of Sales/Marketing and Research all housed under the one roof.
Coversyl 8mg was launched in February 2004 and already contributes 21% of the Company annual turnover.
Coralan, a new treatment for chronic stable angina was registered in November 2006.
In April 2007, Protos, a new treatment for post menopausal osteoporosis was listed on the PBS.
Servier Australia is the local subsidiary of Servier, a leading French research-based pharmaceutical entity, specialising in ethical pharmaceuticals. Employing over 200 people in Australia, its headquarters are in Hawthorn, Melbourne. In 2009 Servier Australia had an annual turnover of $107 million.
Servier Laboratories Limited comprises two principal divisions:
Clinical Research
The management of phase l, ll, lll and lV clinical trials in collaboration with research-based hospitals and general practices throughout Australia.
Sales and Marketing
Sales and Marketing deliver Servier’s portfolio of ethical pharmaceutical products to primary and secondary healthcare professionals
In addition to a team of representatives throughout Australia, to support the operational activities of the above divisions, there is naturally a complete range of professional support functions that include the following: Training, Medical Information (Marketing), Regulatory Affairs, Human Resources, Finance, Information Services, Strategic Coordination, External and Government Relations and Medical Affairs.
Servier Australia offers a range of products in a number of medical areas: cardiovascular disease, especially hypertension and cardiac disease, diabetes and more recently osteoporosis
Would you begin by outlining the key milestones & achievements of the NHMRC in the past four years? The first point is the development of our initiatives on an international…
Would you please introduce The Pharmacy Guild to our readers, giving an insight in its function and its membership? We are the premium body representing community pharmacies in Australia, about…
Earlier this year the company set a crucial step in its internationalization strategy with the acquisition of Ascent. Would you outline the significance of the acquisition within Watson’s global expansion…
We last met you in 2008 as Chair of the Pharmaceuticals Industry Council (PIC), which set itself the goal of doubling the levels of exports, R&D investment, manufacturing, value-added activities,…
Would you outline the commitment of the Ministry to foster a positive business environment for the Australian pharmaceutical industry to prosper? Issues faced by the pharmaceutical industry are not unlike…
You were appointed last year with a specialized portfolio reflecting some of the key priorities on the country’s health care agenda. Would you begin by outlining your mission for your…
You returned to Australia a year ago after spending eight years in Europe with the company. In your view, what were the key changes in the Australian market? Looking at…
As a general medical practitioner with a long experience in the pharmaceutical industry including public policy, advertising, marketing and regulatory issues and a post graduate training in traditional Chinese medicine,…
In trying to be an effective association and positively influence the environment for your members, what have been the main achievements and milestones since you were appointed in 2008? We…
Please introduce Nucleus Network and the role it plays in the Australian pharmaceutical sector. Nucleus Network is an early-phase clinical research business, and is somewhat unique, as it is a…
As a biopharmaceutical company, how have the PBS reforms affected Celgene? Celgene looks at the PBS reforms more positively than negatively. As a company with a smaller product portfolio of…
To begin, would you please introduce GMIA to Pharmaceutical Executive readers? The GMIA is an industry organization. Its six members are: Alphapharm, Apotex, Genepharm, Hospira, Sandoz and Sigma. The GMiA…
See our Cookie Privacy Policy Here